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INTRODUCTION
Asthma is an inflammatory disorder of the lungs causing the 
airways to swell and narrow, shortness of breath, chest tight-
ness, and coughing. Asthma is estimated to affect 300 million 
people worldwide, with a prevalence ranging from 1%-18% 
across different countries.1 The prevalence of asthma is com-
paratively low in the Asia-Pacific region, with a value of 3.9% re-
ported for South Korea in 2004.2 However, asthma prevalence is 
increasing in South Korea, such that values of 7.8%-17.7% were 
reported in 2009 for adults of various ages.3 
Among the factors influencing the onset and course of asth-
ma are environmental agents including allergens, air pollution, 
and tobacco smoke.1 There is evidence that exposure to envi-
ronmental tobacco smoke may both cause adult-onset asthma 
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and worsen existing asthma symptoms in non-smokers.4 Active 
smokers with asthma have poorer symptom control than non-
smokers,5 arising perhaps from increased inflammatory mark-
ers at the cellular level and/or a greater degree of airway re-
modeling.6 Studies of the Cohort for Reality and Evolution of 
adult Asthma in South Korea (‘the COREA cohort’) support this 
assertion. The COREA cohort indicated that smoking was asso-
ciated with a history of exacerbation and more exacerbation-
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related physician visits.7 In subgroup analyses at year 1 of those 
with severe asthma, a longer duration of smoking (≥5 pack-
years versus <5 pack-years) was associated with fixed airway 
obstruction.8 Asthma patients who smoke are also less respon-
sive to treatment with corticosteroids, as demonstrated by ran-
domized controlled clinical trials in Europe9-11 and the United 
States.12 Possible mechanisms for this effect include overex-
pression of the nonfunctional glucocorticoid receptor β sub-
type in smokers6; reduction of histone deacetylase-2 activity, 
presumably caused by cigarette smoke leading to increased ex-
pression of inflammatory genes6; an increase in neutrophil-me-
diated inflammation, which improves upon smoking cessation 
13; and increased leukotriene production.14 
In South Korea, 29.1% of the general population smokes–52.8% 
of men and 5.8% of women.15 Because smoking is so common in 
South Korea, and because of its detrimental effects on asthma 
patients’ symptom control and response to treatment with corti-
costeroids, we sought to determine the prevalence of smoking in 
Korean asthma patients and to compare the asthma medications 
among those who do and do not smoke.
MATERIALS AND METHODS
Study design
A cross-sectional survey was conducted from August 2010 to 
January 2011 (the study period) at 16 urban study sites across 
South Korea. Physicians recorded demographic and clinical 
data on all asthma patients presenting during the study period 
and then recruited a subset of asthma patients for participation 
in the study. Physicians completed a questionnaire for each 
study patient using the patient’s medical records. Each study 
patient completed a questionnaire during the study visit. Ques-
tionnaires were approved by the ethics committees of Hallym 
University Sacred Heart Hospital and Ajou University Hospital. 
The study was also registered with the Korean Research-based 
Pharmaceutical Industry Association (KRPIA). Patients provid-
ed informed consent for study enrollment. 
Study sample
Participating physicians were qualified after 1965, were per-
sonally responsible for treatment decisions for patients with 
asthma, saw >5 patients with asthma who smoke per week, 
and were willing to consent to participate for the duration of 
the study. Twenty-five physicians from 16 study sites located in 
6 South Korea cities (8 sites each in Seoul and Gyunggi provinc-
es) completed a log of the first 40 asthma patients presenting, 
regardless of smoking status or participation in the study. This 
non-identifying data was used to estimate the prevalence of 
smoking in the general asthma patient population. The physi-
cians then recruited 10 smokers and 10 non-smokers each, re-
sulting in a study population of 250 asthma patients who 
smoked and 250 asthma patients who did not smoke. The ma-
jority of participating physicians (84.0%) worked in hospitals, 
whereas the rest (16.0%) worked in clinics.  
The study population included asthma patients between aged 
18-60 who, upon recruitment by the physician, agreed to com-
plete the patient questionnaire in their local language. Patients 
were excluded if they had a diagnosis of chronic obstructive 
pulmonary disease, bronchiectasis, bronchiolitis, cystic fibro-
sis, lung cancer, or pneumonia; had an infection or condition of 
the airway other than asthma; had limited cognitive function-
ing; or had participated in a clinical trial related to asthma in 
the previous 6 months. Both physicians and patients were com-
pensated for their participation.
Questionnaires 
The physician questionnaire included physician-recorded, pa-
tient-specific information on demographics, clinical evaluation, 
smoking history (current, former, or never), asthma medications, 
asthma-related consultation history, and comorbid conditions. 
The patient questionnaire recorded information on smoking his-
tory (current, former, or never), asthma symptoms, asthma treat-
ment regimen, asthma-related resource utilization, and asthma 
control. Quality of life was assessed by the EuroQol (EQ)-5D (The 
EuroQol Group).
Study definitions
Frequency and history of smoking was used to categorize pa-
tients as a current smoker (frequent: >5 cigarettes a day vs in-
frequent: ≤5 cigarettes a day), a never-smoker, or a former 
smoker (someone who stopped smoking at least 6 months 
ago). Asthma-related resource utilization included planned 
and unplanned doctor visits, emergency care, and hospitaliza-
tions. The number of occurrences of each type of resource utili-
zation was totaled over the previous 12 months. The number of 
exacerbations in the previous 12 months, defined as unplanned 
visits for an exacerbation or as emergency treatment or hospi-
talization for asthma, was self-reported by the patient.
The level of asthma control for each study patient was defined 
by the physician per the Global Initiative for Asthma (GINA) 
recommendations.1 Specifically, the physician survey contained 
the schema presented in the GINA guidelines for assessing asth-
ma control. A determination of ‘controlled’ asthma required 
having daytime symptoms and needing rescue treatment less 
than thrice weekly; and having no nocturnal symptoms, no lim-
itations in activities, and normal lung function. If daytime symp-
toms or need for rescue treatment occurred more than twice 
per week, or if any nocturnal symptoms or limitations in activi-
ties were present, or if lung function was <80% of the predicted 
or personal best value, then the patient’s asthma was deemed 
‘partly controlled’. ‘Uncontrolled’ asthma was defined as having 
three or more characteristics of partly controlled asthma.
Asthma medication use was determined by the physician and 
used to define the treatment regimen for each patient. Medica-
Park et al. Volume 7, Number 1, January 2015
32  http://e-aair.org Allergy Asthma Immunol Res. 2015 January;7(1):30-36. http://dx.doi.org/10.4168/aair.2015.7.1.30
tion regimens were classified as 5 ‘steps’ according the GINA 
recommendations.1 At step 1, patients use a short-acting beta-
agonist (SABA) as needed. The recommended add-on therapies 
at steps 2-4 are low-dose inhaled corticosteroids (ICSs), low-
dose ICS plus a long-acting beta-agonist (LABA), and medium- 
or high-dose ICS plus a LABA, respectively. Step 5 incorporates 
the use of oral corticosteroids (OCSs) or anti-IgE treatment. The 
following adjustments were made to the treatment definitions 
to facilitate patient classification.  Bambuterol and tulobuterol 
were defined separately from the other LABAs and not used for 
GINA classification. Ipratropium and tiotropium were excluded 
during the classification process. Chronic use of OCSs was clas-
sified as GINA Step 5. Acute use of OCSs was classified accord-
ing to the other components of the medication regimen.
Statistical analysis
All statistical analyses were conducted using STATA SE v.12.1 
(College Station, TX, USA). Power calculations showed that 250 
smokers and 250 non-smokers were needed to detect a mini-
mum difference of 12.4% in the use of asthma medications be-
tween smokers and non-smokers, assuming a two-sided alpha 
of 0.05, 80% statistical power, and a conservative estimate of 50% 
medication use among smokers. This power calculation applied 
to the original evaluation of potential differences in asthma med-
ications between smokers and non-smokers and was not intend-
ed to test differences according to GINA treatment steps. A de-
scriptive analysis of the patient population with regard to age, 
smoking status, rhinitis, medication use, and exacerbations was 
performed using data from the physician questionnaire. The 
Kappa statistic was computed to assess the level of agreement 
between the physician-determined and patient-reported smok-
ing status. Clinical characteristics, asthma control, healthcare re-
source utilization, and quality of life were assessed descriptively 
according to patient-reported smoking status. Finally, asthma 
medication regimens (defined by the five GINA steps) and quali-
ty of life (i.e., the mean EQ-5D visual analog scale [VAS] scores), 
were assessed according to patient-reported smoking status. P 
values for proportional distributions were calculated using Fish-
er’s exact tests or chi-square analyses, and those for mean VAS 




The characteristics of all asthma patients presenting during 
the study period and patients participating in the study are 
shown in Table 1. Current smoking was recorded for 17.3% of 
patients in the presenting population, former smoking for 
19.2%, and never smoking for 63.5%. Among the 500 patients 
Table 1. Patient characteristics 
Characteristics All presenting patients(N=2,032)*
Study population
(N=471)
Age, mean years (SD)† 52.0 (16.4) 43.5 (12.1)
Age, years 
  <25 106 (5.2) 31 (6.6)
  25-44 549 (27.0) 200 (42.5)
  45-64 863 (42.5) 231 (49.0)
  65-74 340 (16.7) 6 (1.3)
  >75 174 (8.5) 3 (0.6)
Smoking status†
  Current <5 per day 101 (5.0) 56 (11.9)
  Current >5 per day 249 (12.3) 170 (36.1)
  Former smoker 391 (19.2) 55 (11.7)
  Never smoked 1,290 (63.5) 190 (40.3)
Rhinitis†
  Yes 1,195 (58.8) 318 (67.5) 
  No 836 (41.1) 153 (32.5)
Rhinitis treatment
  Yes 1,023 (50.3) 277 (58.8)
  No 952 (46.9) 181 (38.4)
  Missing 57 (2.8) 13 (2.8)
Medication
  ICS/LABA fixed-dose 1,522 (74.9) 346 (73.5)
  Anti-allergic drug 1,039 (51.1) 267 (56.7)
  Leukotriene modifier 1,033 (50.8) 231 (49.0)
  SABA 396 (19.5) 87 (18.5)
  Oral corticosteroids (acute use) 353 (17.4) 85 (18.1)
  Complementary therapy 293 (14.4) 70 (14.9)
  Xanthines 293 (14.4) 61 (13.0)
  ICS 233 (11.5) 47 (10.0)
  Long-acting anticholinergics 134 (6.6) 20 (4.3)
  Oral corticosteroids (chronic use) 51 (2.5) 11 (2.3)
  LABA 27 (1.3) 12 (2.6)
  Anticholinergics 26 (1.3) 8 (1.7)
Exacerbations in past 12 1.2 (2.8) 1.1 (2.8)
*One patient had missing data for smoking status, and one had missing data 
for rhinitis; †Age, smoking status, and rhinitis were physician-determined. SD, 
standard deviation; ICS, inhaled corticosteroids; LABA, long-acting beta-2 ago-
nists; SABA, short-acting beta-2 agonists Values are presented as N (%) unless 
otherwise indicated.










Current smoker (N=226) 202 19 5
Former smoker (N=55) 4 47 4
Never smoked (N=190) 6 13 171
Agreement between physician and patient reports of smoking status was sig-
nificant at P<0.001, κ=  0.82.
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Table 3. Characteristics of study population by smoking status
Study population (N=471) Current smoker (N=212) Former smoker (N=79) Never smoked (N=180) P values
Age, mean years* 43.7 (12.1) 43.6 43.9 43.3 (12.3) 0.60
Gender <0.001†
   Male 56.9%  79.7% 81.0% 19.5%
   Female 43.1%  20.3% 19.0% 80.5%
Years since asthma diagnosis 0.54
   0-5 62.5% 59.9% 70.9% 61.7%
   6-10 17.2% 18.4% 12.7% 17.8%
   11-15 5.1% 6.1% 1.3% 5.6%
   16+ 3.8% 2.8% 3.8% 5.0%
   Not stated 11.4% 12.7% 11.4% 10.0%
Comorbidities‡
   Rhinitis 68.8% 64.2% 70.9% 73.3% 0.13
   Sinusitis 18.1% 21.2% 13.9% 16.1% 0.25
   Hypertension 14.2% 15.6% 17.7% 11.1% 0.28
   Diabetes 5.3% 5.2% 5.1% 5.6% 0.98
   High cholesterol 4.7% 3.3% 8.9% 4.4% 0.13
   Joint disease 3.2% 2.4% 1.3% 5.0% 0.19
   Depression/anxiety 3.0% 3.3% 3.8% 2.2% 0.74
   None reported 18.7% 22.6% 19.0% 13.9%
Asthma control§ 0.88
   Controlled 31.7% 32.3% 36.1% 29.3%
   Partly controlled 44.3% 44.9% 40.9% 44.9%
   Uncontrolled 24.0% 22.8% 22.9% 25.9%
Healthcare utilization
   Planned visit  91.5%  89.6%  93.7%  92.8% 0.08
   Unplanned visit 20.8%  16.5%  20.3%  26.1% 0.10
   Emergency treatment only  10.0%  9.4%  6.3%  12.2% 0.34
   Hospitalizations  10.0%  6.6%  12.7%  12.2% 0.13
Pack-years 0.62
   0 3.6% 3.4% 4.4% 100.0%
   1-5 (low) 32.0% 33.8% 23.9% -
   6-20 (medium) 38.4% 37.8% 41.3% -
   21-31+ (high) 26.0% 25.0% 30.4% -
Exacerbations 0.07
   None 59.3% 63.7% 63.3% 52.8%
   ≥1 40.7% 36.3% 36.7% 47.2%
*Age is patient-reported; †Overall P value. P<0.001 for the comparisons between never smokers and current smokers and between never smokers and former smok-
ers. P=1.0 for the comparison between current and former smokers; ‡Conditions listed represent the most commonly reported comorbidities. SD, standard deviation 
Data on rhinitis were taken from a different portion of the questionnaire than those in Table 1; §Asthma control was defined per GINA criteria.
recruited for the study, 28 had data that could not be linked to 
the original physician record and one had missing data on smok-
ing status, leaving an analyzable study population of 471. Pa-
tients in the study population were younger on average than all 
presenting patients (43.4 vs 52.0 years) and, because of the study 
selection criteria, smoking was much more frequent in the study 
population (48.0%; Table 1). Concomitant rhinitis was common 
in both groups (67.7% in the study population and 58.8% in pre-
senting patients), and the most frequently used asthma medica-
tions in both the study and presenting populations were ICS/
LABA fixed-dose combinations (78.3% and 74.9%, respectively), 
anti-allergic drugs (60.7% and 51.1%, respectively), and leukotri-
ene modifiers (52.4% and 50.8%, respectively).
Physician-patient agreement on smoking status
Within the study population, 212 patients reported smoking 
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currently, 79 smoking formerly, and 180 never smoking (Table 2). 
Correlation between physician-reported and patient-reported 
smoking status was strong (κ=0.82; P<0.001). The most com-
mon mismatch was among physicians designating self-reported 
former smokers as current smokers or never smokers.
Patient characteristics by smoking status 
Patient characteristics according to smoking status (Table 3) re-
vealed substantial differences between men and women in 
smoking behavior. The study population comprised 56.9% men, 
but among current and former smokers, 79.7% and 81.0%, re-
spectively, were men. Conversely, while 43.1% of the total study 
population was female, women represented 80.5% of patients 
who had never smoked. 
Current and never smokers had similar patterns of asthma 
duration, comorbidities, and asthma control. Certain types of 
healthcare resource utilization differed numerically, though 
not statistically significantly, by smoking status (Table 3): 26.1% 
of never smokers (compared to 16.5% of current smokers) had 
an unplanned visit during the previous year, and 12.2% of never 
smokers had been hospitalized (compared to 6.6% of smokers). 
In addition, 47.2% of never smokers had ≥ 1exacerbation dur-
ing the previous year compared to current and former smokers 
(36.3% and 36.7%, respectively).
Asthma medication regimen and quality of life by smoking 
status
There were no statistically significant differences in asthma 
medication regimen between smoking and non-smoking asth-
ma patients (Table 4). Mean quality of life scores by smoking 
status are shown in Table 5. Mean VAS scores increased with in-
creasing asthma control in the combined study population 
(P<0.001) across all smoking categories. Quality of life did not 
differ by smoking status in the combined study population 
(P=0.23), though never smokers with uncontrolled asthma had 
a numerically lower mean quality of life score (58.7) than cur-
rent and former smokers with uncontrolled asthma (62.3 and 
66.9, respectively).
DISCUSSION
This cross-sectional study examined smoking status and med-
ical treatment among asthma patients presenting for medical 
care at clinical practice sites in South Korea. The prevalence of 
current smoking in the presenting population was 17.3%, 
somewhat lower than the value of 26.6% found in the Korean 
NHANES survey,16 but close to that reported in the Asthma In-
sights and Reality in Asia-Pacific study: 19.6% for Korea, 19.1% 
overall.17
The significantly greater proportion of male asthma patients 
who are current smokers, compared to female asthma patients, 
is consistent with statistics from the World Health Organization 
for the general population15 suggesting that a more intense 
need for smoking cessation exists among the former group. 
Community-wide18 and individual19 efforts at smoking cessa-
tion have proven to reduce asthma-related resource utilization 
and improve lung function. 
Despite the higher prevalence of smoking among men, wom-
en in this study had higher odds of having partly controlled or 
uncontrolled asthma than men (OR 1.46; 95% CI 0.64-3.31) in 
multivariate logistic regression analyses (not shown), although 
not statistically significant (P=0.37). The prevalence of current 
smoking among female asthma patients in this study (20.3%) 
was much higher than that reported for the general population 
(5.8%)15 or in previous studies of asthma patients (4.9%).20 Kore-
an women may feel they need to hide their smoking status, 
since smoking by women is not well accepted in Korean society, 
but may be more comfortable revealing their smoking status to 
a physician. 













No asthma   
  medications
3.8% 2.8% 2.5% 5.6%
Unclassifiable 5.5% 6.6% 3.8% 5.0%
GINA step*
  1 2.1% 2.8% 1.3% 1.7%
  2 8.9% 9.4% 10.1% 7.8%
  3 29.1% 25.9% 26.6% 33.9%
  4 47.8% 49.5% 54.4% 42.8%
  5 2.8% 2.8% 1.3% 3.3%
*P=0.41 and 0.46 for the comparisons of the treatment distributions of never 
smokers with current and former smokers, respectively, by chi-square analysis.
GINA, Global Initiative for Asthma 













All* 70.8 (16.4) 70.1 (15.6) 73.6 (17.3) 70.2 (16.9)
   Controlled 77.5 (12.3) 77.2 (13.0) 79.0 (9.6) 77.1 (13.1)
   Partly controlled 70.4 (15.1) 69.8 (14.0) 70.5 (16.9) 71.1 (15.8)
   Uncontrolled 61.5 (17.4) 62.3 (14.4) 66.9 (21.6) 58.7 (18.5)
*ANOVA was performed for VAS score versus asthma control (the first column) 
and for VAS score versus smoking status (the first row). The relationship between 
VAS score and asthma control was statistically significant (P<0.001), but that be-
tween VAS score and smoking status was not (P=0.23). Data are presented as 
mean (SD) EQ-5D VAS score. Reported problems include mobility (some prob-
lems, 13.8%), self-care (some problems, 2.13%), usual activities (some problems, 
16.8%), pain/discomfort (some problems, 36.5%), and anxiety/depression (some 
problems 30.6%). Asthma control was determined according to GINA criteria. 
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This study revealed that physicians in Korea have a very good 
awareness of the smoking behaviors of their asthma patients 
and hence could make appropriate therapy selections based on 
the patients’ smoking status. However, no statistically signifi-
cant differences were observed in the treatment regimens pre-
scribed, suggesting that physicians make treatment decisions 
based on clinical characteristics other than smoking status. 
Neither asthma control nor quality of life differed across smok-
ing status. Similarly, Jang et al.19 reported equivalent improve-
ments in quality of life in smokers and quitters receiving in-
haled fluticasone propionate in a small study of asthma pa-
tients recruited from Soonchunhyang University Bucheon Hos-
pital in Korea. 
Smoking has been shown to decrease the responsiveness of 
asthma patients to ICSs9,10,12,21and the relationship between ICS 
dose and level of smoke exposure.23 Previous studies indicated 
up to 56% of asthma patients in Korea are prescribed ICSs,17,22 
and 83.5% of the current study population used them, either 
alone or in combination with LABAs. Alternative therapies (i.e., 
leukotriene modifiers) are available, but clinical trials are need-
ed to establish their efficacy in asthma patients who smoke.6 
Future observational studies could assess the usage patterns of 
alternative treatments in asthmatic smokers and compare the 
respective levels of asthma control to those of non-smokers.
The current study provides valuable information on how phy-
sicians in Korea treat asthma patients who smoke, yet  several 
limitations exist. First, it is likely that consulting bias affected 
the study outcomes. Patients seeking medical care are more 
likely to be poorly controlled and uncontrolled than patients 
not consulting. Also, the relationship between smoking and 
treatment regimen may have been confounded by the high fre-
quency of prior exacerbations in both smokers and non-smok-
ers, which suggests equivalent levels of asthma severity. The 
study was powered to detect differences in asthma medication 
regimens rather than GINA treatment step, which may have 
hindered detection of statistical significance in the differences 
in treatment step distributions among the smoking subgroups. 
Finally, because the study was designed to include approxi-
mately equal numbers of smoking and non-smoking patients, 
the comparisons between the groups may not fully reflect the 
distinctions between smokers and non-smokers in the general 
asthma patient population. Physicians and patients involved in 
this study may not be representative of care provided for all 
asthma patients in South Korea given the involvement of only 
16 clinical sites in South Korea.
In conclusion, this study showed that in South Korea, physi-
cians’ assessments of smoking status agree well with patients’ 
self-reports, allowing them to make appropriate therapy selec-
tions. However, medication regimens did not differ between 
smokers and non-smokers, suggesting that physicians make 
treatment decisions based on factors other than smoking sta-
tus.  Physicians’ consideration of the patients’ complete clinical 
profile, including smoking status, and need for medical care 
will adequately inform the need for higher-step therapy or al-
ternative agents.
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